Given the new cup record visitors, the organizers at BIO Germany, the working group of bioregions a

Take a look at the most interesting news and products of the process ...
3,078 euros - this award calls on Alcon for a pack Jetrea, the Lauer tax is apparent. Used the substance for the treatment of vitreomakularen traction, an age-dependent progressive eye disease. Cause is an overly strong connection between the vitreous and the macula. The mechanical overload can lead to optical distortion, reduced visual acuity and loss of central vision. The active ingredient Ocriplasmin is a recombinant form of the proteolytic enzyme plasmin. He releases the proteins that cause the excessive train between vitreous and macula and thus contributes to the fact that the traction 2011 academy award nominees is released.
Alcon acquired the rights for the marketing of Jetrea 2011 academy award nominees outside of the USA from the biopharmaceutical Thrombogenics. The Belgian company retained the U.S. rights to the drug, which is there since October 2012 for the treatment of symptomatic vitreomacular adhesion (VMA) allowed. So far, Alcon paid around 165 million euros in upfront and milestone payments to Thrombogenics from - of which alone 90 million euros after treatment of the first patient in Europe. Additional 210 million euros and a profit share be payable on commercial success of Jetrea.
Given the new cup record visitors, the organizers at BIO Germany, the working group of bioregions and host of Life Science Nord were completely satisfied with the now fifth edition of the event in its current form. Plenty of discussion offered the 20 parallel forums on topics such as immunotherapy, bioeconomy, technology transfer and market access. As host of Schleswig-Holstein and Hamburg continued their accents in marine biotechnology and medical technology, with a new master plan will be further strengthened in future these activities. With regard to the latest industry figures the topic financing was, as usual on a high: Are the companies in this country only in survival mode and losing competitiveness? How could a German growth model look like? New starting points for this provided the federal policy. So announced Georg Schütte, State Secretary in the Federal Ministry of Education and Research (BMBF), spontaneously a new initiative in order to explore improvements in the capital market. "We were just born the idea for a new inter-ministerial dialogue with the Economic and Finance Ministry," 2011 academy award nominees Schuette said. Sven Halldorn, Head of Industrial Policy in the Federal Ministry of Economic Affairs, reported on an industrial policy approach to innovation of his house, which is to be presented before the summer break, and stressed. "We dare now to describe biotechnology as a lead market" Lutz slings, State Secretary, Federal Ministry of Health unveiled plans for a new pharmaceutical dialogue before the government.
BMBF funding money was also distributed: Seven founding team were delighted with around 20 million euros from the pot of up competition GO-Bio, an additional 8 million euros received two already funded teams. At the evening event in the temporary buildings, endowed with 2,000 euros each Innovation Award of the bioregions also was given to three research teams. The bar for the next day biotechnology 2011 academy award nominees is high: it will take place in Cologne on 22 and 23 April 2015. "We want the 800-mark crack in the participants" expressed combative Bernward Garthoff of the then host bioregion BIO.NRW.
More than 350 participants found their way on April 8 in the Kongresshaus in Zurich. Organizers Swiss Biotech Association (SBA) and organizer BIOCOM AG spoke of a thoroughly successful event (Picture Gallery on european-biotechnology-news.com): "The move to the new location and the establishment of three parallel sessions in the afternoon 2011 academy award nominees strands evidence of a further increase in interest on the part of the Swiss biotech scene, "said SBA boss Domenico Alexakis. The focus of the event was the presentation of the "Swiss Biotech Report 2014". Its central claim: medical 2011 academy award nominees biotechnology in Switzerland experienced an encouraging upswing. Oreste ghisalba, Member of the Steering Committee of the report and head of the biotech division of the Commission for Technology and Innovation (CTI) in Bern pointed out, however, that caused by the mass immigration initiative problems would have to be getting to the end of 2014 at the latest in the handle to allow the research site Switzerland does not suffer.
Also took advantage of a number of companies the Swiss Biotech Day as a stage for the presentation of news: Santhera boss Thomas Meier works according to his own statement currently hard on the submission of the application for marketing authorization (MAA) of the main product Raxone 2011 academy award nominees for the treatment of Leber's